STOCK TITAN
  1. Home
  2. SGEN

Seagen (SGEN) Stock Price, News & Analysis

SGEN NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
5 252 sessions, December 22, 2022 to December 22, 2023
Largest daily move
+14.5% close of March 13, 2023
1-year change
+75.5% closing prices, December 22, 2022 to December 22, 2023
1-month change
+7.4% closing prices, November 22, 2023 to December 22, 2023

Company Description

SGEN has gained 75.5% over the past year. The last closing price was $228.74.

This page collects what Stock Titan holds for SGEN, including price data and latest news.

Stock Performance

Chart
$—
-
-
Last updated:
+75.5%
Performance 1 year
-
Market Cap
-
Shares outstanding

Seagen (SGEN) closed at $228.74 on December 22, 2023. Over the past 12 months, the price has gained 75.5%.

See what a $1,000 investment in SGEN would be worth today

SGEN Metrics & Rankings

Month to date
+7.3%
View ranking
YTD
+78.0%
View ranking

Price returns through December 22, 2023. Month-to-date and YTD include the first trading day. Ranking links may use different dates.

Latest News

View All
0.00%

Pfizer Completes Acquisition of Seagen

acquisition
+3.29%

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

acquisition
+1.20%

ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

clinical trial
-0.01%

TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

-0.23%

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

fda approval
+0.10%

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

clinical trial
+0.20%

New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate

+0.73%

Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress

earnings
+0.64%

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

clinical trial
+0.64%

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer

Seagen has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 2 with negative movement. Key topics include acquisition, clinical trial, fda approval, earnings. View all SGEN news →

SEC Filings

View All

No SEC filings available for SGEN.

Frequently Asked Questions

What is the current quoted price of Seagen (SGEN)?

The current quoted price of Seagen (SGEN) is $228.74 as of February 13, 2024.